(July 18, 2017, 1:15 PM EDT) -- CHICAGO — AbbVie Inc. and Abbott Laboratories on July 17 moved for judgment as a matter of law in the second AndroGel bellwether trial, arguing that the plaintiff so far has not proven that the testosterone replacement drug caused his heart attack and has not shown that AndroGel’ s warnings were inadequate or that the plaintiff or his doctor were misled about the drug (In Re: Testosterone Replacement Therapy Products Liability Litigation, MDL Docket No. 2545, No. 14-1748, Jesse Mitchell, et al. v. AbbVie, Inc., et al., No. 14-9178, N.D. Ill.)....